This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Sixth Take: Looking at Momelotinib & Pacritinib in treating Myelofibrosis

Ticker(s): SRRA, CTIC

Who's the expert?

Institution: University of Utah

  • Professor in the Division of Hematology and Hematologic Malignancies & Huntsman Cancer Institute Investigator at the University of Utah.
  • Member of the Cell Response and Regulation Program and the Imaging, Diagnostics, and Therapeutics Program.
  • Research focuses on elucidating the molecular basis of hematological diseases to discover their either somatic or germline underlying mutations and then determine the functions of the mutations.

Interview Questions
Q1.

Please describe your clinical practice and research relating to MF.

Added By: joe_mccann
Q2.

On a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for Momelotinib? on Pacritinib?

Added By: joe_mccann
Q3.

What do you expect the Danazol arm to do on A) TSS B) TI C) SVR?

Added By: joe_mccann
Q4.

What do you expect the Momelotinib arm to do on A) TSS B) TI C) SVR?

Added By: joe_mccann

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.